RESEARCH TRIANGLE PARK, N.C. & MUNICH, Germany--(BUSINESS WIRE)--Sept. 5, 2006--The largest safety data set among alpha-1 antitrypsin augmentation (AAT) therapies compiled over the longest period of time reaffirms the clinical safety and tolerability of Prolastin(R) (Alpha1-Proteinase Inhibitor (Human)) in treating patients with AAT deficiency. Presented today at the 2006 Annual Congress of the European Respiratory Society, safety data collected since the original approval of Prolastin(R) in 1987 now represent more than 18 years of clinical experience and 40,826 patient-years of exposure. Results demonstrate that Prolastin(R) continues to be well tolerated with respect to drug interactions, overdose, and abuse potential.
